Search

everythinglearnresearchcommunity

for

Search:↓

Transplant success has improved with better immunosuppressive drugs and donor matching.

Early detection and intensive treatment of diseases caused by Staphylococcus aureus toxins are crucial for reducing severe health effects.

Folliculitis decalvans is a rare scalp condition causing scarring hair loss, treated with long-term antibiotics and other medications, but it often comes back and is hard to manage.

Lichen planopilaris is a chronic, scarring hair loss condition with no definitive cure, requiring accurate diagnosis and treatment to manage symptoms.

Hormonal treatments can help with acne, especially in women, by lowering androgen levels or blocking their effects.

The study found that Keratosis Pilaris Atrophicans is a genetic skin condition that starts in childhood, involves inflammation and scarring, and current treatments are only somewhat effective.

Hormones and genetics affect hair growth and patterns, with some changes reversible and others not.

Nanotechnology in dermatology shows promise for better drug delivery and treatment effectiveness but requires more safety research.

Insulin resistance contributes to hormone imbalances in many women with polycystic ovary syndrome.

Graft-versus-host disease is a complication where donor immune cells attack the recipient's body, often affecting the skin, liver, and gastrointestinal tract.

Cancer treatments often cause hair disorders, significantly affecting patients' quality of life, and better management methods are needed.

The document explains different types of hair loss, their causes, and treatments, and suggests future research areas.

The conclusion is that genetic changes in the glucocorticoid receptor can lead to conditions affecting stress response, immunity, and metabolism, requiring personalized treatment.

The document concludes that research on sulfatase inhibitors should continue due to their potential in treating various diseases, despite some clinical trial failures.

Hormonal treatments are effective for severe or persistent acne and should be used with other acne therapies, considering potential side effects.

The conclusion is that we need more effective hair loss treatments than the current ones, and these could include new drugs, gene and stem cell therapy, hormones, and scalp cooling, but they all need thorough safety testing.

In STSD patients, the body compensates for low androgen levels by increasing another enzyme's activity.

New methods to make oxasteroids show promise for medical treatments like osteoporosis and breast cancer.

Certain hormone treatments can improve acne and related conditions in women.

Intravaginal testosterone cream improves sexual satisfaction and reduces vaginal discomfort in postmenopausal women on breast cancer treatment without affecting hormone levels.

New sulfur-containing steroid analogs show promise for more targeted medical treatments.

Polymers increased skin permeation and stability of steroid hormones in liposomal formulations.

SLE affects lungs and kidneys similarly due to immune complexes.

Alopecia Areata is a complex, unpredictable autoimmune hair loss condition with limited treatment options and a significant psychological impact.

Familial frontal fibrosing alopecia affects premenopausal women too, and early diagnosis is important, but no proven medication exists yet.

The conclusion is that better understanding and more research are needed to effectively manage follicular and scarring disorders in skin of color, with an emphasis on patient education and cultural awareness.

Antiandrogens have important biological effects, but more research is needed to understand them fully and compare their effectiveness and side effects to other treatments.

Topical vitamin D is useful for some skin conditions but not effective for others, and more research is needed.

COVID-19 can cause various skin issues, including rashes and hair loss, which usually heal on their own and don't always indicate severe illness.

Combination therapy with steroids and pimecrolimus improved or stabilized hair loss in most patients with Frontal Fibrosing Alopecia, who also had a high rate of hypothyroidism.